A phase II investigation of pentostatin in metastatic malignant melanoma
β Scribed by Michael Grever; Paul Brager; Eric Kraut; Earl Metz
- Publisher
- Springer US
- Year
- 1992
- Tongue
- English
- Weight
- 121 KB
- Volume
- 10
- Category
- Article
- ISSN
- 0167-6997
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The National Cancer Institute of Canada Clinical Trials Group conducted a phase II study of spirogermanium given daily for 5 days every 3 weeks to previously untreated patients with malignant melanoma. In 21 evaluable patients one complete response was seen (response rate 5%). Disease progression oc
## Abstract Trimetrexate glucuronate, a nonclassical antifolate, was administered to 14 patients with recurrent and progressive metastatic malignant melanoma. Thirteen patients were evaluable for response and toxicity. Five patients had received prior treatment consisting of immunotherapy (one pati